Abstract
To the Editor: Swinnen et al. (Dec. 20 issue) reported an 11.4 percent incidence of post-transplantation lymphoproliferative disorder associated with the administration of OKT3 in heart-transplant recipients.1 This experience is not consistent with that at the Minneapolis Heart Institute, where a prophylactic OKT3 regimen has been used in high-risk heart-transplant recipients for 45 months.2 Since May 3, 1987, 39 recipients of heart transplants have received OKT3; 31 were weaned from steroids three to six months after transplantation and have been maintained on a steroid-free regimen of cyclosporine and azathioprine. One- and three-year survival rates were 93 percent and 91 percent,. . .
Original language | English (US) |
---|---|
Pages (from-to) | 1437-1439 |
Number of pages | 3 |
Journal | New England Journal of Medicine |
Volume | 324 |
Issue number | 20 |
DOIs | |
State | Published - May 16 1991 |
Externally published | Yes |
ASJC Scopus subject areas
- General Medicine